Troglitazone should not be used in Type I diabetes or for the treatment of diabetic keto-acidosis.
Not available in USA, UK or Japan.
- TRADE NAMES: Prelay (Sankyo); Rezulin (Pfizer)
- INDICATIONS: Management of Type II diabetes (noninsulin-dependent diabetes mellitus (NIDDM) also known as adult-onset diabetes)
- CLASS: Antidiabetic, CYP3A4 inducer, Thiazolidinedione
- HALF-LIFE: 16–34 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cholestyramine, Digoxin, Terfenadine
- See adverse reactions attributed to class:
HEPATOTOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
